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Purpose: To develop a direct, simple and extraction-free spectrophotometric method for the 
simultaneous estimation of valsartan and ezetimibe in pharmaceuticals. 
Methods: A spectrophotometric method for the determination of valsartan and ezetimibe was developed 
using acidic dyes, namely, bromophenol blue (BPB) and bromocresol green (BCG). The method was 
based on selective ion-pair formation between valsartan and the acidic dye. The yellow coloured ion-pair 
induces a bathochromic shift in the spectrum with maximum absorbance at 425 and 428 nm for BPB 
and BCG, respectively. The developed method was validated as per ICH guidelines.  
Results: With BPB, the ion-pair formed obeyed Beer`s law in the ranges 5 - 40 and 1 - 50 µg/mL for 
valsartan and ezetimibe, respectively. The assay data for valsartan and ezetimibe were, 99.39 ± 0.53 
and 98.17 ± 0.91 %, respectively, for the commercial formulation, and 99.41 ± 0.48 and 98.16± 0.89 %, 
respectively, for the developed formulation. The method was validated and the correlation coefficient for 
valsartan and ezetimibe were 0.995 and 0.999, respectively. Recovery was in the range 99.3 - 100.3 %. 
Conclusion: The proposed method is reproducible, accurate, robust and suitable for the simultaneous 
quantitative analysis of the studied drugs in bulk and dosage formulation.  
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INTRODUCTION 
 
Valsartan (3-methyl-2- [pentanoyl-[ [4-[2-(2H-
tetrazol-5-yl) phenyl] phenyl] methyl]amino] -
butanoic acid) is an angiotensin II receptor 
antagonist acting on the AT1 subtype. It is 
indicated for the treatment of high blood 
pressure, congestive heart failure (CHF), and 
post-myocardial infarction (MI). Ezetimibe 
((3R, 4S)-1-(4-fluorophenyl)-3-((3S)-3-(4-
fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxy-
phenyl)-2-azetidinone) is an anti-
hyperlipidemic medication used to lower 
cholesterol levels. It acts by decreasing 
cholesterol absorption in the intestine. 
 
A literature survey on valsartan indicates that 
several methods are available including those 
based on high performance liquid 
chromatography (HPLC) [1,2] and chiral 
HPLC [3]. Valsartan and hydrochlorothiazide 
have been determined in tablets 
simultaneously by HPLC and first derivative 
UV Spectrophotometry [4]; tandem mass 
spectrometry has been used for the 
determination of nebivolol and valsartan in 
biological fluids [5], while valsartan and 
amilodipine besylate in capsules have been 
analyzed using reverse phase HPLC [6]. 
Ezetimibe has been determined in biological 
fluids using HPLC [7] and in pharmaceutical 
dosage forms [8], Stress degradation studies 
have been carried out on ezetimibe using 
HPLC [9] while simvastatin and ezetimibe 
have been simultaneously quantified in a 
drug product using HPLC
 
[10]. Although 
studies on insulin-sensitizing agents 
(metformin and rosiglitazone) in combination 
with ezetimibe and valsartan for the treatment 
of fatty liver disease have been reported [11], 
to the best of our knowledge, no method for 
the simultaneous analysis of valsartan and 
ezetimibe in a combined dosage form has 
been reported. 
 
Ion-pair extraction technique is a well 
recognized spectrophotometric method. An 
ion-pair is usually formed between the drug 
molecule (a basic compound) and an anionic 
dye such as bromophenol blue (BPB) and 
bromocresol green (BCG). The drug-dye 
complex formed is either extracted using a 
suitable solvent or measured directly using a 
spectrophotometer [12]. The extraction 
technique is often fraught with complications 
such as incomplete extraction and formation 
of emulsion between the hydrocarbon solvent 
and the solution containing the basic 
compound. Spectrophotometric procedures 
are popular for their sensitivity and simplicity; 
thus, ion-pair extractive spectrophotometry 
has received considerable attention for the 
quantitative determination of many 
pharmaceutical compounds [12].  
 
The aim of the present study is to develop a 
method for the simultaneous spectro-
photometric assay of valsartan and ezetimibe 
by ion-pair formation using the dyes, 
bromophenol blue (BPB) and bromocresol 




Apparatus and reagents  
 
A uv/visible spectrophotometer (Agilent 8453, 
China) with spectral bandwidth of 2 nm, 
wavelength accuracy of ± 0.5 nm and 1 cm 
quartz cells was used for all absorbance 
measurements. Spectra were automatically 
obtained from the system software 
ChemStation. A Perkin Elmer UV/vis 
spectrophotometer (Lambda 12) was used for 
intermediate precision. Vortex cyclomixer 
was used for obtaining solution of uniform 
concentration. The formulations were 
compressed with the automated Cadmach 
(Model# CMD4) Compression machine using 
the software, AIM, version 3.6 and presented 
below. Labnet Hermle Z200A centrifuge 
device was used for centrifugation of solution 
during the study. 
 
Methanol of chromatographic grade, 
bromophenol blue and bromocresol green 
(both 0.04 % solution) were procured from E. 
Merck. Reference standard of valsartan (Lot 
# TRC-200306011) and ezetimibe (5-YM-
118-1) were obtained from Toronto Research 
Ramachandran et al  
Trop J Pharm Res, December 2011;10 (6): 811 
Chemicals, Canada. Valsartan and ezetimibe 
powders were obtained from Matrix Pvt. Ltd 
and Glenmark Pvt Ltd, India, respectively. 
The commercial formulation of valsartan 
(Valzar 80 mg Lot# 06039005) was obtained 
from Torrent Pharmaceuticals Ltd while 
ezetimibe (Zeteze 10 mg Lot# 1997604) was 
obtained from Ranbaxy Laboratories Ltd, 
India 
 
Preparation of combined tablet formula-
tion 
 
Ezetimibe (50 %), lactose (20 %) and 
Plasdone K29/32 (3 %) were pre-mixed with 
water for 1 min in Pro-C-Ept granulator at an 
impeller speed of 1000 rpm. The granulator 
speed was increased to 2300-2500 rpm 2 
min later following the addition of water. The 
mass was sieved through #18-mesh sieve 
and dried at 60 °C in an oven. The dried 
granules were sized through #30-mesh sieve, 
blended valsartan (38 %), Eudragit RLPO (36 
%), microcrystalline cellulose (14 %), 
hydroxypropyl methylcellulose (10 %), 
magnesium stearate (1 %) and fumed silica 
(1 %) in a V-cone blender (8 rpm) to form a 
homogeneous mix and compressed using 11 
mm round shaped standard punch set was 
used on a 16-station rotary tablet press 
(Cadmach, model CMD4, India). Advanced 
Instrumentation Monitor (AIM) software 
(Metropolitan Computing Corporation, USA) 
was used with the tablet press to determine 
the compression force required to give tablets 
of approximately equal hardness in the study. 
 
Selection of dye 
 
The complex formation ability of valsartan 
and ezetimibe were first tested with 10 
different dyes in the pH range of 0 to 10. The 
dyes used (with their pH range in 
parenthesis) are: eosin (0 to 3), cresol red 
(0.2 to 1.8), methyl orange (2.8 to 4.6), 
bromophenol blue (2.8 to 4.6), methyl red 
(4.2 to 6.3), bromocresol green (3.6 to 5.2), 
bromothymol blue (6.0 to 7.6), thymol blue 
(1.2 to 2.8 and 7.8 to 9.5), phenolphthalein 
(8.2 to 10.0) and methylene blue. The 
analysis was repeated with three different 
solvents, namely, methanol, acetonitrile and 
acetone. BPB and BCG both showed similar 
results at 425 and 428 nm, respectively. 
Preliminary trials performed for the extraction 
of valsartan-dye ion pair with two immiscible 
solvents - dichloromethane and chloroform 
followed by UV analysis - showed that there 
was no absorbance at 425 nm for BPB, thus 
indicating that the complex formed is stable in 
methanol only.  
 
Optimisation of solvent  
 
Optimisation of conditions is necessary for 
rapid and quantitative formation of colored 
ion-pair complexes with maximum stability 
and sensitivity. Maximal absorbance was 
observed in methanol solution and this 
solvent was found to be suitable for both BPB 
and BCG while chloroform and 
dichloromethane were not.  
 
Optimisation of dye concentration 
 
Four different standard solutions of valsartan 
containing 10, 20, 30 and 70 µg/mL were 
prepared by diluting valsartan stock solution 
(500 µg/mL) with methanol in 50 mL standard 
volumetric flasks. To each concentration of 
valsartan, varying concentrations of dye were 
prepared from the stock solution (400 µg/ mL) 
to constitute the final dye concentration of 8, 
16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96 and 
104 µg/mL, and the volumes made up with 
methanol. The solutions were shaken well in 
a vortex shaker for uniform concentration and 
scanned spectrophotometrically. The opti-
mised dye concentration was found to be 72 
µg/mL, based on the validation data obtained 
and this concentration was applied in all 
subsequent analyses. 
 
Standard and sample solutions 
 
Twenty tablets were accurately weighed and 
finely powdered. An accurately weighed 
portion of the powder equivalent to 80 mg of 
valsartan ((Valzaar 80 mg) and 10 mg of 
ezetimibe (Zeteze 10 mg) was transferred to 
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a 200 mL standard volumetric flask; the 
solution was made up to the mark using 
methanol and centrifuged for 20 minute at 
2500 rpm. The solution was suitably diluted 
to contain 24 µg/mL valsartan and 3 µg/mL 
ezetimibe. A dye concentration of 72 µg/mL 
was added to the final solution and made up 
to the mark with methanol. The combined 
formulation of valsartan (80 mg) and 
ezetimibe (10 mg) was formulated in-house 
and the solutions for the analysis were 
prepared as per the procedures described 
above.  
 
A stock standard solution of 400 µg/mL 
valsartan and 50 µg/ mL ezetimibe was 
prepared and suitably diluted with methanol 
to obtain final concentrations within Beer 
Lambert`s range, i.e., 24 µg/mL valsartan and 
3 µg/mL ezetimibe, in a 50 mL volumetric 
flask. A dye (BPB) concentration of 72 µg/mL 
was added to the final solution and made up 
to the mark with methanol. The solutions 
were vortexed to obtain a uniform 
concentration. Both standard and sample 
solutions were scanned using Agilent UV 
spectrophotometer. 
 
Method validation  
 
Linearity and range  
 
Calibration curve was constructed with 
various concentrations of Valsartan and 
Ezetimibe in the range of 5- 40 µg/mL and 1- 
50 µg/ mL respectively. The linearity graph 
was plotted with absorbance against 
concentration.  
 
Stability of the complexes  
 
The absorbance of nine different 
concentrations (in the range of 5 - 50 µg/mL) 
of valsartan-dye was measured periodically 




The intermediate precision study was 
performed by scanning the solution of 
valsartan-dye complexes using an alternative 





Recovery experiments were conducted to 
determine the accuracy of the proposed 
method. In order to detect possible 
interaction with excipients, the recovery of the 
sample solution was studied by spiking a 
known quantity of the drug in the range 20 - 
30 µg/mL and 2 - 4 µg/mL for valsartan and 
ezetimibe respectively with placebo (the 
placebo was obtained by mixing all the 




The stochiometry of the ion pair was 
determined by Job`s method using equimolar 
solution. In this method the complex is made 
to form at different mole fraction and the 




The results obtained were subjected to 
statistical analysis using two tailed student’s 
t-test using MS Excel 2007. Differences were 




The developed method was optimised and 
validated as per international conference on 
harmonisation (ICH) guidelines [13]. The 
stochiometric relationship of the complex 
formed was estimated using Job`s method. 
The method was applied to obtain the assay 




The factors affecting color development, 
reproducibility and adherence to Beer`s law 
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Table 1: Optical characteristics of valsartan and ezetimibe (n = 5) 
 
BPB BCG 
Parameter Valsartan Ezetimibe Valsartan Ezetimibe 
λmax (nm) 423 250  428 250 
Stability (h) 120 120 120 120 
Beer`s law range (µg/mL) 5- 40 1- 50 5- 35 1- 50 
Molar absorptivity 
a
 1.5 X 10
4
 8.9 X 10
4
 1.45 X 10
4
 8.5 X 10
4
 
Regression data     
Slope (a) 0.033 0.036 0.032 0.037 
Intercept (b) 0.006 0.012 0.042 0.008 
Correlation coefficient (r) 0.9950 0.9990 0.9930 0.9990 
RSD (%)
a







; BPB = bromophenol blue; BCG = bromocresol green  
 
 
Table 2: Recovery data for combined dosage form of valsartan and ezetimibe using bromophenol blue 
(mean ± SD, n = 5)  
    
µg/mL 





20 20.02 ± 0.04 100.11 ± 0.25 0.25 
25 25.06± 0.09 100.26± 0.35 0.35 Valsartan 
30 30.02± 0.08 100.06± 0.28 0.28 
2 1.99± 0.01 99.73± 0.42 0.42 
3 2.99± 0.01 99.53± 0.38 0.38 Ezetimibe 
BPB 
4 4.01± 0.02 100.16± 0.45 0.45 
20 19.98 ± 0.03 100.04 ± 0.17 0.16 
25 24.96± 0.05 99.83± 0.20 0.20 Valsartan 
30 29.97± 0.06 99.89± 0.19 0.19 
2 1.99± 0.01 99.29± 0.40 0.4 
3 2.98± 0.01 99.35± 0.30 0.3 Ezetimibe 
BCG 
4 3.99± 0.02 99.86± 0.48 0.48 
a
 CV- Coefficient of variance (in %) 
 
The correlation coefficient of the calibration 
curves of valsartan and ezetimibe were 0.995 
(at 425 nm) and 0.999 (at 250 nm), 
respectively in the concentration range 5 - 40 
and 1 - 50 µg/ mL, respectively.  The 
valsartan - complex formed were stable for 
up to 120 h at ambient temperature. The 
intermediate precision analysis was 
performed using an UV spectrophotometer 
from another manufacturer (Perkin Elmer) 
The concentration of valsartan – BPB dye 
complexes were linear in the range 5 - 40 
µg/mL with a correlation coefficient of 0.9934 
and 0.9954 using both Perkin Elmer and 
Agilent spectrophotometers, respectively. 
The accuracy (% recovery) was performed 
and it was found to be in the range 99.3 - 




The composition of ion-pair was determined 
by    Job’s    method [14]    using    equimolar  
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Table 3: Assay results for valsartan and ezetimibe in tablet formulations 
 













value of t 
Valsartan (80 mg) 99.39± 0.53 0.54 99.41± 0.40 0.40 0.97 BPB
a
 Ezetimibe (10 mg) 98.17± 0.91 0.92 98.15± 0.89 0.92 0.98 
Valsartan (80 mg) 99.41± 0.48 0.48 99.44± 0.37 0.37 0.94 BCG
b




 bromocresol green; CV = coefficient of variation (in %); SD = standard deviation; 
c
 commercial 
formulation; DF = formulation prepared in-house 
 
valsartan solution at concentrations of 239 
and 229 µM for BPB and BCG, respectively. 
The plot reached maximum value at a mole 
fraction of 0.5, indicating complex formation 




Figure 1: Job`s method of continuous variation for 
valsartan-dye complex 
 
Application of the developed method to 
pharmaceutical formulations 
 
The developed method was applied to 
analyse a commercial product and a tablet 
formulation developed in-house, both of 
which contained valsartan and ezetimibe. 
The UV spectrum was recorded and their 
drug contents were calculated by comparing 
the absorbance of the sample at 425 nm 
(using BPB dye) and 250 nm against a 
standard sample. Drug contents of both the 
standard and samples were calculated for a 
concentration of 24 µg/mL Valsartan and 




Anionic dyes such as BPB and BCG form 
ion-association complexes selectively with 
one of the drug molecules, i.e., valsartan, 
forming a yellow colored complex. This might 
be due to the electron-donating groups 
(tetrazole and amino butanoic acid) present 
in the valsartan structure [15]. Valsartan 
forms ion-pair complex selectively with the 
dye, as indicated by the formation of a yellow 
coloured complex. The other drug, ezetimibe, 
does not interact with the dye due to the 
presence of fluorine [16]. Fluorine, being 
highly electronegative, does not make 
available any free electron in the molecule to 
interact with the acidic dye and hence it does 
not show a characteristic color change. 
Valsartan dye complex behaves as a single 
unit held together by electrostatic force of 
attraction [14]. T he absorbance of valsartan 
shifted from 250 nm to 425 nm (bathochromic 
shift) after the complex formation with the dye 
solution.  
 
The method developed was validated 
according to ICH guidelines, being found to 
adhere to Beer`s law in the concentration 
range of 5 - 40 µg/mL and 1 - 50 µg/ mL for 
valsartan and ezetimibe, respectively (when 




Both valsartan and ezetimibe were 
successfully determined in commercial 
tablets containing the drugs separately as 
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well as in combined formulation. The ion-pair 
complex formation takes place 
instantaneously and the color formation is 
stable. Excipients used in the pharmaceutical 
formulation did not interfere in the analysis. 
Based on the results obtained, the proposed 
method is accurate, precise, reproducible, 
economical and can be employed for routine 
analysis of valsartan and ezetimibe in a 
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